Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Cascadian Therapeutics, Inc. | d334284d8k.htm |
Exhibit 17.1
One Sansome Street, 30th Floor
San Francisco, CA 94104
January 17, 2017
Cascadian Therapeutics, Inc.
2601 Fourth Avenue, Suite 500
Seattle, Washington 98121
Attention: Julia M. Eastland, Chief Financial Officer, Vice President and Secretary
Dear Ms. Eastland:
Effective immediately, I hereby resign from the Board of Directors.
I have a fundamental disagreement with management and the Board as to the Company’s contemplated financing, given the extreme dilutive impact it would have on existing shareholders. I believe it is my fiduciary duty as a director to make this concern clearly known to you and the Board.
I believe that Tucatinib, the Company’s promising drug candidate for treating HER2+ breast cancer, is valuable, worth far more than the market value of Cascadian. With cash and short term investments of $71.6m as of September 30, 2016, there is no immediate need to massively dilute the Company. I believe a continued exploration of strategic alternatives, about which I am optimistic, is in all stockholders’ best interests, and would likely alleviate the need for any further dilution. The outcome of this strategic process could be the outright sale of Cascadian at a price reflective of Tucatinib’s true value and/or shareholder participation in the future success of Tucatinib.
Because I do not support, and do not wish to be seen as supporting, the proposed financing, and because management and the board have nonetheless elected to proceed, I feel I have no choice but to resign.
| Very truly yours, |
| /s/ Mark N. Lampert |
| Mark N. Lampert |
| Cc: | Christopher S. Henney |
Gwen A. Fyfe, M.D.
Richard L. Jackson, Ph.D.
Steven P. James
Ted W. Love, M.D.
Scott D. Myers
Daniel K. Spiegelman, M.B.A.